Ohkubo Yusuke, Ohmura Shin-Ichiro, Ishihara Ryuhei, Miyamoto Toshiaki
Department of Rheumatology, Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan.
Case Rep Rheumatol. 2022 Aug 23;2022:3124887. doi: 10.1155/2022/3124887. eCollection 2022.
The coronavirus disease (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 has led to rapid progress in vaccine development to prevent the spread of the disease. Although COVID-19 vaccines have excellent effectiveness in reducing morbidity and disease severity with minor adverse reactions, some patients develop late hypersensitivity events as autoimmune reactions such as rheumatoid arthritis, lupus nephritis, and vasculitis following COVID-19 vaccination. Herein, we describe a case of pneumonitis following COVID-19 mRNA vaccination in a patient with rheumatoid arthritis, which resolved spontaneously.
由严重急性呼吸综合征冠状病毒2引起的冠状病毒病（COVID-19）大流行促使疫苗研发取得了快速进展，以防止该疾病的传播。尽管COVID-19疫苗在降低发病率和疾病严重程度方面具有出色的有效性，且不良反应较小，但一些患者在接种COVID-19疫苗后会出现迟发性超敏反应，如类风湿性关节炎、狼疮性肾炎和血管炎等自身免疫反应。在此，我们描述了1例类风湿性关节炎患者在接种COVID-19 mRNA疫苗后发生肺炎的病例，该病例自行缓解。
